Momenta Pharmaceuticals Inc. (MNTA) today filed a complaint for patent infringement against Teva Pharmaceutical Industries Ltd (TEVA). In the complaint presented today to the US District Court in Massachusetts, Momenta accused TEVA of two patent infringement cases. According to the complaint, Momenta Pharmaceuticals alleges that Teva Industries has infringed on its patents by making material preparations to sell a generic enoxaparin product that has been manufactured using the methods in Momenta’s patents.
From Court Documents:
“Momenta it is the assignee and owner of two patents related to the manufacture of the generic versions of pharmaceuticals made from enoxaparin sodium. The United States Patent and Trademark Office issued the patents in August, 2009 and September, 2010, respectively. In July, 2010, Momenta began marketing the first generic enoxaparin sodium product. Meanwhile, in February, 2010, Teva announced its intention to sell a generic enoxaparin as soon as it obtains FDA approval.
Momenta alleges that Teva has infringed on its patents by making material preparations to sell a generic enoxaparin product that has been manufactured using the methods in plaintiffs’ patents. Plaintiffs seek injunctive relief and damages.”
During Friday’s trading session, MNTA shares have gains 0.52% to $13.52. TEVA is up 0.16% to $50.20.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply